CMS & Incyte Collabs to Develop Povorcitinib in China

CMS and Incyte collaborate to develop vitiligo drug Povorcitinib in China and Southeast Asia

Overview

China Medical System Holdings (CMS) and Incyte have entered into a collaboration and license agreement for the development and commercialisation of povorcitinib, a selective oral JAK1 inhibitor, to research, develop, register and commercialise the product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the Territory) and a non-exclusive license to manufacture the product in CMS’ Territory.

Terms of the Agreement

• Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
• CMS will receive an exclusive license to develop and commercialise and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.

Words from CEO: Incyte

Herve Hoppenot, Chief Executive Officer, Incyte said, “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!